GlassScriptPhysician profile
Barbara L Simon
NPI 1104854322
$767.89
in general payments reported to CMS, 2019-2025
13 companies · $49.13 in 2025
The $49.13 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $260 · 2023: $101 · 2024: $46.99 · 2025: $49.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $219.12 | 2021-2023 | Kristalose |
| Biohaven Pharmaceutical Holding Company LTD. | $125.01 | 2022 | |
| Glaxosmithkline, LLC. | $67.49 | 2021-2023 | Bexsero, Pediarix |
| Cranial Technologies, INC | $59.95 | 2021-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $55.46 | 2021 | |
| Merck Sharp & Dohme LLC | $52.93 | 2021-2025 | Enflonsia, Gardasil 9, Vaxneuvance |
| Sanofi Pasteur INC. | $46.63 | 2021-2023 | |
| Sobi, INC | $32.86 | 2023 | |
| Pfizer INC. | $27.79 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $26.88 | 2021 | |
| Lnhc, INC | $19.83 | 2025 | Zelsuvmi |
| Astrazeneca Pharmaceuticals LP | $19.20 | 2024 | Flumist Quadrivalent |
| Seqirus USA INC | $14.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.